Lowenstein Sandler represented Crown Laboratories, Inc. (Crown Laboratories), a leading, fully integrated skin care company, and Hildred Capital Partners LLC, a private investment firm, in the acquisition of North American rights to Keri® from GlaxoSmithKline (GSK), a company that researches, develops, and manufactures innovative pharmaceutical medicines, vaccines, and consumer health care products. The transaction involved an equity investment from Greenspring Associates, Inc.; other current equity investors in Crown include Hildred Capital Partners, LLC and Montreux Equity Partners, LLC. Financial terms of the transaction were not disclosed.
Keri has a long and successful history in the market, supported by dermatologists and health care practitioners across the world. The acquisition provides Crown Laboratories with another major skin care brand with a rich heritage that has provided elegant therapeutic formulations to consumers for decades. This acquisition marks the sixth GSK product that Crown Laboratories has acquired in the past five months. In December 2018, Lowenstein represented Crown Laboratories and Hildred Capital Partners in the acquisition of the North American distribution rights of five OTC consumer brands from GSK.
The Lowenstein team included Herschel S. Weinstein, Sam E. Khan, Mitchell McDonald, James C. Shehan, Matthew P. Hintz, , Michael A. Buxbaum, , Matthew Tippy, Erica Perlmutter, Jeffrey M. Shapiro, and Jack Sidorov.
